Heterocyclic STING Modulators for Immune Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and cancers lack effective modulation of the STING pathway, leading to inadequate control of type I interferon and pro-inflammatory cytokine production, which can cause excessive inflammation and immune dysregulation.
Innovation Solution
Development of heterocyclic compounds that act as STING modulators, capable of activating or inhibiting the STING pathway to regulate type I interferon production, thereby treating autoimmune diseases, cancers, and other conditions by administering these compounds or their pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for autoimmune diseases and cancers, then existing therapeutic approaches are maintained, but effective modulation of the STING pathway is lacking, leading to inadequate control of type I interferon and pro-inflammatory cytokine production
Solution Approach 1:
The patent employs parameter changes by developing compounds with varying chemical structures (different heterocyclic groups, substituents at positions R1-R8) to modulate STING pathway activity. The compounds include diverse structural parameters such as different heterocycles (pyrazole, imidazole, triazole), various substituents (halogen, alkyl, alkoxy, amino groups), and different core structures (pyrimidoindole, imidazopyridine), allowing precise control over STING activation or inhibition to achieve reliable control of type I interferon production while maintaining adaptability for different disease states
2Reliability
If STING pathway is activated to enhance immune response, then type I interferon production increases for cancer treatment, but excessive type I interferon production causes autoimmune diseases and chronic inflammation
Solution Approach 1:
The patent applies inversion by developing compounds that can act as either STING activators or inhibitors depending on the specific disease context. The same chemical framework (compounds of formula I) can be tuned to produce opposite effects: some derivatives activate STING to enhance anti-tumor immunity, while others inhibit STING to reduce pathogenic interferon in autoimmune diseases. This bidirectional capability allows the immune response to be enhanced when needed without causing excessive inflammation, as the direction of modulation can be inverted based on therapeutic requirements
Solution Approach 2:
The patent uses parameter changes to control the balance between immune activation and suppression. By modifying specific parameters in the chemical structure (such as the type of heterocycle, position and nature of substituents R1-R8, and core scaffold), the compounds can be precisely tuned to achieve desired levels of STING modulation. This allows optimization of immune response enhancement for cancer treatment while preventing excessive inflammation, as small parameter changes can shift the compound from activator to inhibitor or adjust the potency to therapeutic ranges
Data Source
AI summary
Disclosed herein are heterocyclic compounds that may be used as STING modulators, the process for synthesis and to the use of such compounds in treatment of various diseases including cancers.